Clindamycin is effective against staph infections and has FDA approval for treating several types, including skin infections, bone and joint infections, and lower respiratory infections caused by Staphylococcus aureus. It works against both common staph (MSSA) and, in many cases, drug-resistant staph (MRSA), though resistance is a real concern that requires proper testing before use.
How Well Clindamycin Works Against Staph
In a hospital study of patients with staph bloodstream infections, clindamycin achieved a microbiological cure in 82% of cases, compared to 84% for other antibiotic regimens. That puts it in a comparable range for straightforward staph infections. However, patients with more severe disease or infections that had spread to multiple sites had lower cure rates and higher mortality, which is true of most antibiotics in those situations.
For uncomplicated skin and soft tissue infections, which are the most common reason people take clindamycin for staph, the drug performs well. It penetrates skin, muscle, and bone tissue effectively, which is why it’s also a go-to option for staph-related bone infections (osteomyelitis). The Infectious Diseases Society of America includes clindamycin in its treatment guidelines for community-acquired MRSA skin infections, making it one of the oral antibiotics doctors reach for when MRSA is suspected but the infection isn’t life-threatening.
Types of Staph Infections It Treats
Clindamycin covers a broad range of staph-related infections:
- Skin and soft tissue infections: abscesses, cellulitis, wound infections, and infected bites
- Bone and joint infections: both acute osteomyelitis caused by staph and longer-term bone infections as part of a combination approach
- Lower respiratory infections: community-acquired pneumonia and aspiration pneumonia, though it’s not a first-line choice for these
- Bloodstream infections (septicemia): typically used alongside other treatments in serious cases
For skin infections specifically, you can expect to feel some improvement within 24 to 48 hours. Visible signs that the infection has stopped spreading typically appear after 48 to 72 hours, and fever usually resolves closer to the 72-hour mark. If you don’t see any improvement after two days, that’s a signal to follow up with your provider, as resistance or a deeper infection may be at play.
The Resistance Problem
Clindamycin resistance in staph is common enough that it can’t be assumed to work without testing. Resistance rates vary by region and by the type of staph. In one large study from China, about 19.5% of staph isolates were resistant to clindamycin. MSSA strains showed resistance rates between 15% and 37% depending on the population studied.
What makes clindamycin tricky is a phenomenon called inducible resistance. Some staph bacteria appear susceptible to clindamycin on a standard lab test but carry a hidden resistance gene that activates during treatment. This can cause the antibiotic to stop working mid-course. A special lab test called the D-zone test can detect this. Without it, roughly a third of MRSA and MSSA isolates that look clindamycin-susceptible are actually capable of developing resistance during treatment.
This is why your doctor may order a culture and sensitivity test before prescribing clindamycin, especially for MRSA. If the lab report says “clindamycin susceptible” and the D-zone test is negative, the drug is a reliable choice. If the D-zone test is positive, your provider will likely switch to a different antibiotic to avoid treatment failure.
The C. Diff Risk
The most significant downside of clindamycin is its association with Clostridioides difficile infection, a potentially serious intestinal condition that causes severe diarrhea and colon inflammation. Among all antibiotics studied, clindamycin carries the highest risk. A large community-based study found that clindamycin had an adjusted odds ratio of 25.4 for C. diff, meaning people who took it were roughly 25 times more likely to develop the infection than those who didn’t take antibiotics. For comparison, common alternatives like amoxicillin had an odds ratio of just 2.0, and doxycycline showed essentially no increased risk at all.
This doesn’t mean everyone who takes clindamycin will get C. diff. The overall incidence is still relatively low. But it does mean that if you develop watery diarrhea, abdominal cramping, or fever during or shortly after a course of clindamycin, those symptoms deserve prompt attention. The risk is higher in older adults and people who have recently been hospitalized or taken other antibiotics.
Typical Dosing for Staph Skin Infections
For adults with skin and soft tissue staph infections, the standard oral dose is 300 to 450 mg taken every six to eight hours. More serious infections requiring IV treatment typically use 600 mg every eight hours. Treatment courses for uncomplicated skin infections generally run 7 to 10 days, though bone infections require much longer courses.
For children, dosing is weight-based, generally 20 to 30 mg per kilogram of body weight per day, divided into doses every six to eight hours. Guidelines for MRSA bone, joint, and skin infections allow doses up to 40 mg per kilogram per day, though most clinicians cap it at 30 for tolerability since higher doses increase gastrointestinal side effects.
When Clindamycin Is a Good Fit
Clindamycin fills a specific niche in staph treatment. It’s most useful when the patient has a penicillin allergy, when a community-acquired MRSA skin infection needs an oral antibiotic, or when the infection involves bone where clindamycin’s tissue penetration is an advantage. It’s also one of the few oral options that works against many MRSA strains, which matters because most staph antibiotics effective against MRSA are IV-only.
It’s less ideal as a first choice for serious bloodstream infections or when resistance testing hasn’t been done. For simple staph skin infections where MRSA isn’t suspected, other antibiotics with lower C. diff risk are often preferred. The decision usually comes down to local resistance patterns, whether MRSA is likely, and the specific type and severity of the infection.